Thrivent Financial for Lutherans Sells 3,741 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Thrivent Financial for Lutherans decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) by 49.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,788 shares of the medical research company’s stock after selling 3,741 shares during the period. Thrivent Financial for Lutherans’ holdings in Bio-Rad Laboratories were worth $1,593,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. AIA Group Ltd lifted its stake in Bio-Rad Laboratories by 203.1% in the fourth quarter. AIA Group Ltd now owns 97 shares of the medical research company’s stock worth $41,000 after acquiring an additional 65 shares during the period. Romano Brothers AND Company purchased a new stake in Bio-Rad Laboratories in the fourth quarter worth $43,000. Atlas Capital Advisors LLC purchased a new position in Bio-Rad Laboratories during the second quarter valued at $50,000. Quantbot Technologies LP purchased a new position in Bio-Rad Laboratories during the third quarter valued at $62,000. Finally, Ellevest Inc. lifted its position in Bio-Rad Laboratories by 350.0% during the third quarter. Ellevest Inc. now owns 216 shares of the medical research company’s stock valued at $90,000 after buying an additional 168 shares during the period. Institutional investors own 64.35% of the company’s stock.

Insider Activity

In related news, EVP Timothy S. Ernst sold 1,746 shares of the firm’s stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $486.43, for a total transaction of $849,306.78. Following the sale, the executive vice president now owns 2,671 shares of the company’s stock, valued at $1,299,254.53. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 17.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Credit Suisse Group raised their price target on Bio-Rad Laboratories from $640.00 to $680.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Royal Bank of Canada raised their price target on Bio-Rad Laboratories from $571.00 to $579.00 and gave the company an “outperform” rating in a report on Friday, February 17th. began coverage on Bio-Rad Laboratories in a report on Thursday. They issued a “buy” rating for the company. Finally, TheStreet upgraded Bio-Rad Laboratories from a “d+” rating to a “c” rating in a report on Thursday, February 16th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $653.00.

Bio-Rad Laboratories Trading Up 0.5 %

Shares of NYSE:BIO opened at $382.14 on Friday. The company has a current ratio of 5.56, a quick ratio of 4.28 and a debt-to-equity ratio of 0.12. The company has a market cap of $11.32 billion, a PE ratio of -58.43 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 12-month low of $344.63 and a 12-month high of $572.70. The stock has a 50 day moving average of $447.80 and a 200 day moving average of $441.76.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last released its quarterly earnings results on Thursday, May 4th. The medical research company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.10. Bio-Rad Laboratories had a positive return on equity of 4.10% and a negative net margin of 7.01%. The company had revenue of $676.80 million for the quarter, compared to analyst estimates of $689.28 million. During the same quarter in the prior year, the firm posted $4.94 EPS. Bio-Rad Laboratories’s quarterly revenue was down 3.3% compared to the same quarter last year. As a group, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 14.55 EPS for the current year.

Bio-Rad Laboratories Company Profile

(Get Rating)

Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.

Featured Stories

Want to see what other hedge funds are holding BIO? Visit to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with's FREE daily email newsletter.